CR11577A - Vacunas contra la malaria - Google Patents

Vacunas contra la malaria

Info

Publication number
CR11577A
CR11577A CR11577A CR11577A CR11577A CR 11577 A CR11577 A CR 11577A CR 11577 A CR11577 A CR 11577A CR 11577 A CR11577 A CR 11577A CR 11577 A CR11577 A CR 11577A
Authority
CR
Costa Rica
Prior art keywords
vaccines against
antigen
against malaria
rts
fusing
Prior art date
Application number
CR11577A
Other languages
English (en)
Inventor
Dominique Ingrid Lemoine
Florence Emilie Jeanne Francoise Wauters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40584700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11577(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CR11577A publication Critical patent/CR11577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a un componente para una vacuna contra la malaria que comprende:a) una particula inmunogena RTS,S y/o b) una particula inmunogena que se deriva de la proteina CS de una o mas cepas de P. vivax y el antigeno S de la Hepatitis B y opcionalmente el antigeno S sin fusionar, o c) una particula inmunogena que comprende RTS, CSV-S y opcionalmente el antigeno S sin fusionar, y d) un agente estabilizante que comprende un agente estabilizante con al menos un grupo funcional tiol, o sus mezclas.
CR11577A 2007-12-21 2010-07-21 Vacunas contra la malaria CR11577A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1576207P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
CR11577A true CR11577A (es) 2010-09-03

Family

ID=40584700

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11577A CR11577A (es) 2007-12-21 2010-07-21 Vacunas contra la malaria

Country Status (22)

Country Link
US (1) US20100272745A1 (es)
EP (1) EP2234637A2 (es)
JP (1) JP2011507816A (es)
KR (1) KR20100109556A (es)
CN (1) CN102026657A (es)
AP (1) AP2010005296A0 (es)
AR (1) AR071741A1 (es)
AU (1) AU2008339980A1 (es)
BR (1) BRPI0822098A2 (es)
CA (1) CA2708716A1 (es)
CL (1) CL2008003808A1 (es)
CO (1) CO6300963A2 (es)
CR (1) CR11577A (es)
DO (1) DOP2010000189A (es)
IL (1) IL206308A0 (es)
MA (1) MA32030B1 (es)
MX (1) MX2010006984A (es)
PE (1) PE20091528A1 (es)
TW (1) TW200940086A (es)
UY (1) UY31569A1 (es)
WO (1) WO2009080715A2 (es)
ZA (1) ZA201004304B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142278A1 (en) * 2012-03-22 2013-09-26 New York University Plasmodium vivax vaccine compositions
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
SG10202012205XA (en) 2015-11-06 2021-01-28 Adjuvance Technologies Inc Triterpene saponin analogues
CN105233296B (zh) * 2015-11-24 2018-08-17 江苏省农业科学院 用于鸭病毒性肝炎活疫苗的耐热冻干保护剂及其制备方法和应用
GB201608821D0 (en) * 2016-05-19 2016-07-06 Isis Innovation Vaccines
EP3615039A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
IL292991A (en) 2017-04-25 2022-07-01 Adjuvance Tech Inc Triterpene saponin analogs
AU2018350887A1 (en) 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
JP2022526334A (ja) 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新たなタウ種を標的化することによるタウオパチー障害の処置の方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
AU2088992A (en) * 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
DE69732029T2 (de) * 1996-04-26 2006-02-23 Merck & Co., Inc. Dna enthaltende impfstoffen
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
CA2302554C (en) * 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
CA2375829A1 (en) * 1999-06-02 2000-12-07 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CN1882360A (zh) * 2003-11-21 2006-12-20 辉瑞产品公司 抗生素作为疫苗佐剂的用途
KR20070008578A (ko) * 2004-02-02 2007-01-17 타녹스 인코퍼레이티드 신규한 ＩｇＥ 에피토프의 확인
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
WO2007079351A2 (en) * 2005-12-15 2007-07-12 Aeras Global Tb Vaccine Foundation Novel prime-boost combinations of attenuated mycobacterium
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions

Also Published As

Publication number Publication date
MX2010006984A (es) 2010-10-25
IL206308A0 (en) 2010-12-30
CN102026657A (zh) 2011-04-20
BRPI0822098A2 (pt) 2015-06-30
AR071741A1 (es) 2010-07-14
JP2011507816A (ja) 2011-03-10
AP2010005296A0 (en) 2010-06-30
US20100272745A1 (en) 2010-10-28
AU2008339980A1 (en) 2009-07-02
DOP2010000189A (es) 2010-08-15
CA2708716A1 (en) 2009-07-02
WO2009080715A3 (en) 2009-11-12
PE20091528A1 (es) 2009-10-29
KR20100109556A (ko) 2010-10-08
UY31569A1 (es) 2009-08-03
TW200940086A (en) 2009-10-01
EP2234637A2 (en) 2010-10-06
WO2009080715A2 (en) 2009-07-02
MA32030B1 (fr) 2011-01-03
CL2008003808A1 (es) 2011-03-11
ZA201004304B (en) 2012-11-28
CO6300963A2 (es) 2011-07-21

Similar Documents

Publication Publication Date Title
CR11577A (es) Vacunas contra la malaria
MX2019008974A (es) Vacunas contra el coronavirus porcino.
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
MX2016012845A (es) Vacuna contra el virus de la diarrea epidemica porcina.
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
CU20220050A7 (es) Vacunas contra el coronavirus
EA201071087A1 (ru) Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а
CU20200037A7 (es) Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb)
JOP20190088A1 (ar) نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
CU20150018A7 (es) Composición para el tratamiento de la infección por hepatitis b o coinfección por hepatitis b/hepatitis d
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
CO6150189A2 (es) Vacunas para malaria
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
UY31285A1 (es) Vacunas
BR112017002496A2 (pt) agente de controle contra a síndrome reprodutiva e respiratória porcina
UY36394A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
CL2007000526A1 (es) Antigeno vacunal quimerico contra el virus de la influenza aviar, ia, que contiene el segmento extracelular de la hemaglutinina de la envoltura del virus de ia y el segmento extracelular de la proteina cd154; y composicion que lo comprende.
EP4149540A4 (en) MANIPULATION OF CORONAVIRUS SPIKE PROTEINS AS VACCINE ANTIGENS, THEIR DESIGN AND USES
MX391930B (es) Vacuna contra la fiebre aftosa.
BR112022015313A2 (pt) Vacina de hpv
WO2020012428A8 (en) New vaccines against avian reoviruses
MX2011006516A (es) Terapia de combinacion de virus de hepatitis c.
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
MX2010007876A (es) Vectores virales recombinantes y composicion de vacuna para leishmaniasis.
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)